Evidence map›Paper›PMID 40796933›Full record

ArticleScientific reports2025

GPER1 is involved in shaping tumor immune microenvironment and its expression is decreased in NSCLC tumorigenesis.

Zhenhua Li, Chao Xie, Jingjing Cui, Hui Xu, Dingbiao Li

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zhenhua Li *Department of Thoracic Surgery, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, 650051, People's Republic of China.
Chao Xie *Department of Thoracic Surgery, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, 650051, People's Republic of China.
Jingjing CuiDepartment of Nephrology and Rheumatology, Kunming Children's Hospital, Kunming, 650228, People's Republic of China.
Hui XuAnning First People's Hospital Affiliated to Kunming University of Science and Technology, Kunming, 650302, People's Republic of China. xuhui2014803@163.com.
Dingbiao LiDepartment of Thoracic Surgery, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, 650051, People's Republic of China. lidb88@163.com.

Funding

Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province 2017DG004National Natural Science Foundation of China 82460698Yunnan Provincial Department of Science and Technology-Kunming Medical University Applied Basic Research Project 202301AY070001-173
6 · The paper itself

Abstract

G-protein coupled estrogen receptor 1 (GPER1) is involved in estrogen response and associated with tumorigenesis in several solid tumors, and we previously reported that its positive expression rate is more than 80% in lung cancer. However, GPER1 has been less studied during the tumorigenesis in non-small cell lung cancer (NSCLC). We used Lung Adenocarcinoma (LUAD) and Lung Squamous Cell Carcinoma (LUSC) data from the Cancer Genome Atlas and Gene Expression Omnibus databases, and self-sequencing data of whole transcriptome of A549 cells for research. Firstly, the expression of GPER1 in adjacent tissues and cancer tissues was compared. Then, according to the median of GPER1, LUAD and LUSC samples in the data set were assigned into GPER1 high and low expression group, respectively. The hub genes were enriched and analyzed. Additionally, the association between GPER1 expression and immune related responses were explored. We obtained GPER1-inhibited and -activated differentially expressed genes (DEGs) from the self-sequencing data. Finally, the GPER1-related competitive endogenous RNA (ceRNA) network was constructed and verified by experiments. The expression of GPER1 in cancer tissues was decreased when compared with that in healthy tissues. The GPER1 gene has good diagnostic value as a differentiator between cancer and normal samples in LUAD- and LUSC-related datasets. Fourteen and thirteen hub genes were identified in LUAD and LUSC, respectively. They were all enriched in the pathways of actin cytoskeleton regulation, extracellular matrix assembly, PI3K-Akt signaling pathway. In addition, GPER1 was significantly associated with immune cells infiltration and expression of common immune checkpoints, and its low expression could predict benefit from immune checkpoint blockade (ICB) treatment in LUSC. The whole-transcriptome sequencing data of A549 cells were analyzed to obtain 132 GPER1 repression- and 39 GPER1 activation-related mRNA, and 13 hub genes were finally screened. Further, the GPER1-related transcription factor (TF)-miRNA-mRNA network and lncRNA/circRNA-miRNA-mRNA ceRNA networks were constructed. Finally, confirmatory studies demonstrated that the hub genes and MAPK signaling pathway were regulated by GPER1, and knockdown of GPER1 expression caused F-actin cytoskeleton rearrangement and promoted cell migration in A549 cells. The expression of GPER1 was decreased during the tumorigenesis in NSCLC. GPER1 was significantly associated with immune cells infiltration and immune checkpoints expression in both LUAD and LUSC, and its low expression could predict benefit from ICB treatment in LUSC. In addition, we report a ceRNA network that may provide new insight into the roles of GPER1 in NSCLC development.

Indexed as

CarcinogenesisCarcinoma, Non-Small-Cell LungLung NeoplasmsReceptors, EstrogenReceptors, G-Protein-CoupledTumor MicroenvironmentA549 CellsGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansSignal TransductionGPER1 protein, humanReceptors, EstrogenReceptors, G-Protein-CoupledCeRNA networkG-protein coupled estrogen receptor 1Non-small cell lung cancerTumorigenesisTumor immune microenvironment

Identifiers

PMID40796933
PMCPMC12343848

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.